Sangamo Therapeutics, Inc. (SGMO) Receives Average Rating of “Hold” from Brokerages
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $8.67.
Several research firms recently weighed in on SGMO. Zacks Investment Research downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Wedbush reiterated a “neutral” rating and set a $4.00 target price (down from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. Finally, ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th.
Sangamo Therapeutics (SGMO) traded up 0.862% during mid-day trading on Tuesday, hitting $8.775. The company had a trading volume of 294,639 shares. The firm’s 50 day moving average is $8.85 and its 200 day moving average is $5.93. The company’s market capitalization is $631.26 million. Sangamo Therapeutics has a 52 week low of $2.65 and a 52 week high of $10.50.
Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $4.14 million. Sangamo Therapeutics had a negative return on equity of 50.76% and a negative net margin of 380.44%. Sangamo Therapeutics’s quarterly revenue was down 12.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) earnings per share. On average, equities research analysts predict that Sangamo Therapeutics will post ($0.93) EPS for the current year.
In other news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the transaction, the vice president now directly owns 35,517 shares in the company, valued at $355,170. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 19,639 shares of company stock worth $184,765 over the last 90 days. Company insiders own 8.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in SGMO. Blair William & Co. IL increased its position in shares of Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $108,000. Fox Run Management L.L.C. purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $126,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 780 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Sangamo Therapeutics during the first quarter valued at about $154,000. Institutional investors and hedge funds own 58.25% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics, Inc. (SGMO) Receives Average Rating of “Hold” from Brokerages” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/sangamo-therapeutics-inc-sgmo-receives-average-rating-of-hold-from-brokerages.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.